
IgA Nephropathy (IgAN) - Pipeline Insight, 2024
Description
IgA Nephropathy (IgAN) - Pipeline Insight, 2024
DelveInsight’s, “IgA Nephropathy – Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
IgA Nephropathy: Overview
IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is not known what causes IgA deposits in the glomeruli. In more than 10% of affected families, it is inherited. Each person may have a different set of signs and symptoms from IgAN. The Most common symptoms are: Hematuria and Proteinuria, Swelling in ankles and High Blood pressure. Urine test, Blood test, Glomerular Filtration rate, Kidney Biopsy are some of the procedures that helps in the diagnosis of IgA Nephropathy. There is no cure for IgA nephropathy, but treatments can help to prevent more damage to your kidneys.
""IgA Nephropathy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IgA Nephropathy pipeline landscape is provided which includes the disease overview and IgA Nephropathy treatment guidelines. The assessment part of the report embraces, in depth IgA Nephropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve IgA Nephropathy.
This segment of the IgA Nephropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IgA Nephropathy Emerging Drugs
- Atrasentan: Chinook Therapeutics
- Sparsentan: Travere Therapeutics
Further product details are provided in the report……..
IgA Nephropathy: Therapeutic Assessment
This segment of the report provides insights about the different IgA Nephropathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in IgA Nephropathy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
IgA Nephropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IgA Nephropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgA Nephropathy drugs.
IgA Nephropathy Report Insights
- IgA Nephropathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing IgA Nephropathy drugs?
- How many IgA Nephropathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IgA Nephropathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IgA Nephropathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for IgA Nephropathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Aravive
- Aduro BioTech
- Alnylam Pharmaceuticals
- Chinook Therapeutics
- Transcenta Holding
- Novartis Pharmaceuticals
- Ionis Pharmaceuticals
- Merck Serono
- ZymoGenetics
- Cemdisiran
- BION 1301
- Batiraxcept
- TST 004
- LNP023
- IONIS-FB-LRx
- Atacicept
Table of Contents
80 Pages
- Introduction
- Executive Summary
- IgA Nephropathy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Pregistration)
- Comparative Analysis
- Sparsentan: Travere Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early stage products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- IgA Nephropathy Key Companies
- IgA Nephropathy Key Products
- IgA Nephropathy- Unmet Needs
- IgA Nephropathy- Market Drivers and Barriers
- IgA Nephropathy- Future Perspectives and Conclusion
- IgA Nephropathy Analyst Views
- IgA Nephropathy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.